**APPENDIX TABLE 1.** Eight phase 3 studies included in the analysis

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study number | Study objective | Study design | Treatment arms | Study, N\* | Duration |
|
| 30632NCT00072774 | Efficacy, safety in MDD  | Randomized DB, placebo-controlled, fixed dose | Desvenlafaxine 100 mgDesvenlafaxine 200 mgDesvenlafaxine 400 mgPlacebo | 470 | 8 weeks |
| 33233NCT00277823 | Efficacy, safety in MDD | Randomized DB, placebo-controlled, fixed dose | Desvenlafaxine 50 mg/dDesvenlafaxine 100 mg/dPlacebo | 451 | 8 weeks |
| 33326NCT00300378 | Efficacy, safety in MDD | Randomized DB, placebo-controlled, fixed dose | Desvenlafaxine 50 mg/dDesvenlafaxine 100 mg/dPlacebo | 485 | 8 weeks |
| 33534NCT00384033 | Efficacy, safety in MDD | Randomized, DB, placebo- and, comparator-controlled, fixed-dose | Desvenlafaxine 50 mg/dDesvenlafaxine 100 mg/dDuloxetine 60 mg/dPlacebo | 616 | 8 weeks |
| 335927NCT00798707 | Efficacy, safety in MDD | Randomized, DB, placebo-controlled, fixed-dose | Desvenlafaxine 25 mg/dDesvenlafaxine 50 mg/dPlacebo | 699 | 8 weeks |
| 336235NCT00863798 | Efficacy, safety in MDD | Randomized, DB, placebo-controlled, fixed-dose | Desvenlafaxine 10 mg/dDesvenlafaxine 50 mg/dPlacebo | 673 | 8 weeks |
| 336436NCT01121484 | Efficacy, safety in MDD; perimenopausal and postmenopausal women | Randomized, DB, placebo-controlled, fixed-dose | Desvenlafaxine 50 mg/dPlacebo | 434 | 10 weeks (8-week primary endpoint) |
| 441537NCT00824291 | Efficacy, safety in MDD; functional outcomes in employed patients | Randomized, DB, placebo-controlled, fixed-dose | Desvenlafaxine 50 mg/dPlacebo | 427 | 12 weeks |

\*Total number of patients in the safety population (all randomized patients who took at least 1 dose of study medication).

DB, double-blind; MDD, major depressive disorder; OL, open-label.